

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) Publication number:

**0 683 233 A2**

(12)

**EUROPEAN PATENT APPLICATION**(21) Application number: **95107621.5**(51) Int. Cl.<sup>6</sup>: **C12P 21/02, C12N 1/19,  
C12N 1/21**(22) Date of filing: **18.05.95**(30) Priority: **18.05.94 JP 103994/94**(43) Date of publication of application:  
**22.11.95 Bulletin 95/47**(84) Designated Contracting States:  
**BE CH DE DK ES FR GB IT LI NL SE**(71) Applicant: **THE GREEN CROSS CORPORATION**  
**3-3, Imabashi 1-chome**  
**Chuo-ku**  
**Osaka-shi**  
**Osaka 541 (JP)**(72) Inventor: **Ohda, Toyoo, The Green Cross**  
**Corp. C. Res. Lab.**  
**25-1, Shodai-Ohtani 2-chome**  
**Hirakata-shi,**  
**Osaka (JP)**  
Inventor: **Ohtani, Wataru, The Green Cross**  
**Corp. C. Res. Lab.**  
**25-1, Shodai-Ohtani 2-chome**  
**Hirakata-shi,**  
**Osaka (JP)**  
Inventor: **Ohya, Tomoshi, The Green Cross**  
**Corp. C. Res. Lab.**  
**25-1, Shodai-Ohtani 2-chome**  
**Hirakata-shi,**  
**Osaka (JP)**  
Inventor: **Kuwae, Shinobu, The Green Cross****Corp. C. Res. Lab.****25-1, Shodai-Ohtani 2-chome****Hirakata-shi,****Osaka (JP)**Inventor: **Tomomitsu, Kenji, The Green Cross**  
**Corp. C.****Res. Lab.,****25-1, Shodai-Ohtani 2-chome****Hirakata-shi,****Osaka (JP)**Inventor: **Kobayashi, Kaoru, The Green Cross**  
**Corp. C.****Res. Lab.,****25-1, Shodai-Ohtani 2-chome****Hirakata-shi,****Osaka (JP)**Inventor: **Ohmura, Takao, The Green Cross**  
**Corp. C.****Res. Lab.,****25-1, Shodai-Ohtani 2-chome****Hirakata-shi,****Osaka (JP)**(74) Representative: **Hansen, Bernd, Dr.**  
**Dipl.-Chem. et al**  
**Hoffmann, Eitle & Partner,**  
**Patentanwälte,**  
**Arabellastrasse 4**  
**D-81925 München (DE)**(54) **Process for producing recombinant human serum albumin.**

(57) A process for producing recombinant human serum albumin is disclosed, which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques in a medium that contains an amino acid, preferably at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, tryptophan, valine, isoleucine, phenylalanine, cysteine and arginine, more preferably histidine. The process can significantly increase the yield of human serum albumin over that produced by known processes.

**EP 0 683 233 A2**

FIELD OF THE INVENTION

This invention relates to the improvement of a process for producing recombinant human serum albumin (to be referred to as "HSA" hereinafter) by culturing a host transformed by means of gene manipulation techniques.

BACKGROUND OF THE INVENTION

HSA is a main component of plasma proteins and is used in pharmaceutical preparations for the treatment of massive hemorrhage, shock, burn injury, hypoproteinemia, fetal erythroblastosis and the like.

Currently, HSA is produced mainly as a product from fractions of collected blood. However, such a production process is economically disadvantageous, and the supply of blood is sporadic. In addition, blood itself is also problematic in that it often contains undesirable substances such as hepatitis virus.

In order to solve such problems, attempts have been made to produce HSA by fermentation of microorganisms in which the HSA gene was introduced, thereby making use of the recently developing recombinant DNA techniques. However, even such recombinant DNA techniques cannot give satisfactory results in terms of the industrial mass production of HSA.

As a consequence, great concern has been directed toward the establishment of an industrial process for producing recombinant HSA in a large amount with a low cost.

SUMMARY OF THE INVENTION

An object of the present invention is to increase productivity of recombinant HSA in a process for the production thereof by means of gene engineering techniques, particularly to provide a large scale HSA production process which is effected by simple changes in the culture conditions of an HSA-producing host.

As a result of intensive investigation in order to solve the above-described problems, the present inventors have found that productivity of HSA can be increased when an HSA-producing host, prepared by gene manipulation techniques, is cultured in an amino acid-containing medium.

Thus, the present invention relates to a process for producing recombinant HSA which comprises culturing an HSA-producing host, prepared by gene manipulation techniques, in an amino acid-containing medium. More particularly, the present invention relates to a process for producing recombinant HSA, comprising:

(1) preparing a culture medium containing at least one amino acid selected from the group consisting of alanine (to be referred to as "Ala" hereinafter), aspartic acid (to be referred to as "Asp" hereinafter), arginine (to be referred to as "Arg" hereinafter), cysteine (to be referred to as "Cys" hereinafter), glutamic acid (to be referred to as "Glu" hereinafter), histidine (to be referred to as "His" hereinafter), isoleucine (to be referred to as "Ile" hereinafter), phenylalanine (to be referred to as "Phe" hereinafter), serine (to be referred to as "Ser" hereinafter), tryptophan (to be referred to as "Trp" hereinafter) and valine (to be referred to as "Val" hereinafter), and (2) culturing an HSA-producing host in said culture medium.

In another embodiment of the invention, the culture medium contains at least one amino acid selected from the group consisting of Ala, Asp, Glu, His, Ser, Phe, Trp and Val.

In a further embodiment of the invention, the culture medium contains at least one amino acid selected from the group consisting of Ala, Asp, His, Ser, Trp and Val.

In an additional embodiment of the invention, the culture medium contains at least one amino acid selected from the group consisting of Ala, Arg, His, Phe, Ser, Trp and Val.

In another embodiment of the invention, the culture medium contains His.

The culture medium contains the amino acid(s) as described in the media above in an amount of from 0.08 to 20 w/v %.

Additionally, the HSA-producing host may be a yeast strain.

DETAILED DESCRIPTION OF THE INVENTION

The HSA-producing host to be used in the present invention is not particularly limited, provided that it is a cellular host prepared via gene manipulation techniques. Any of the hosts disclosed in published reports, and those which will be developed in the future may be used. Illustrative examples of such hosts include microorganisms (*Escherichia coli*, a yeast strain, *Bacillus subtilis* and the like), as well as animal cells, which have been made into HSA-producing cells by gene manipulation techniques. According to the present invention, it is desirable to use as the host a strain of yeast, especially belonging to the genus

*Saccharomyces*, such as *Saccharomyces cerevisiae*, the genus *Pichia*, such as *Pichia pastoris*, the genus *Kluyveromyces*, such as *Kluyveromyces lactis* or the genus *Hansenula*, such as *Hansenula polymorpha*. An auxotrophic strain or an antibiotic sensitive strain may also be used. Specific examples thereof include G418 sensitive strains such as *Saccharomyces cerevisiae* AH22 (*a*, *his* 4, *leu* 2, *can* 1),  
 5 *Pichia pastoris* GTS115 (*his* 4) and *Kluyveromyces lactis* MW98-8c ( $\alpha$ , *uraA*, *arg*, *lysK*<sup>+</sup>, *pKD1*<sup>0</sup>). It is preferable to use *Pichia pastoris*, particularly *Pichia pastoris* GTS115.

Preparation of HSA-producing host, production of HSA by its culturing and isolation and recovery of HSA from the cultured broth are all carried out in accordance with known methods which may be modified slightly. For example, preparation of an HSA-producing host (or an HSA-producing strain) may be effected  
 10 using a process in which a natural human serum albumin gene is used (JP-A-58-56684 corresponding to EP-A-73646, JP-A-58-90515 corresponding to EP-A-79739 and JP-A-58-150517 corresponding to EP-A-91527), a process in which a modified human serum albumin gene is used (JP-A-62-29985 and JP-A-1-98486 corresponding to EP-A-206733), a process in which a synthetic signal sequence is used (JP-A-1-240191 corresponding to EP-A-329127), a process in which a serum albumin signal sequence is used (JP-  
 15 A-2-167095 corresponding to EP-A-319641), a process in which a recombinant plasmid is introduced into a chromosome (JP-A-3-72889 corresponding to EP-A-399455), a process in which hosts are fused (JP-A-3-53877 corresponding to EP-A-409156), a process in which a mutation is generated in a methanol containing medium, a process in which a mutant AOX<sub>2</sub> promoter is used (EP-A-506040), a process in which HSA is expressed in *B. subtilis* (JP-A-62-215393 corresponding to EP-A-229712), a process in which HSA is  
 20 expressed in yeast (JP-A-60-41487 corresponding to EP-A-123544, JP-A-63-39576 corresponding to EP-A-248657 and JP-A-63-74493 corresponding to EP-A-251744) and a process in which HSA is expressed in *Pichia* (JP-A-2-104290 corresponding to EP-A-344459). (The term "JP-A" as used herein means an "unexamined published Japanese patent application")

Of these methods, the method in which mutation is induced in a methanol-containing medium is carried  
 25 out in the following manner.

A transformant of an appropriate host, preferably a *Pichia* yeast, illustratively a strain GTS115 (NRRL deposition No. Y-15851), is obtained in the usual manner by introducing a plasmid, containing a transcription unit by which HSA is expressed under the control of the AOX<sub>1</sub> promoter, into the AOX<sub>1</sub> gene region of the host (cf. JP-A 2-104290). This transformant hardly grows in a medium containing methanol. In  
 30 consequence, this transformant is cultured in a methanol-containing medium to generate mutation, and a strain capable of growing in the medium is isolated. Methanol concentration in the medium may range, for example, from 0.0001 to 5%. The medium may be either synthetic or natural. The culturing may be carried out, for example, at a temperature of from 15 to 40 °C for approximately from 1 to 1,000 hours.

Culturing of the HSA-producing host (namely the method for the production of HSA) may be effected by  
 35 each of the methods disclosed in the above patents, by a method in which producer cells and the product are obtained in high concentrations by a fed-batch culture which method is carried out by gradually supplying a high concentration solution of glucose in appropriate small amounts to avoid high concentration substrate inhibition against the producer cells (JP-A-3-83595), by a method in which the HSA productivity is improved by the addition of fatty acids to the culture medium (JP-A-4-293495 corresponding to EP-A-  
 40 504823 and U.S. Patent 5,334,512) or by a method in which coloring of HSA is inhibited by culturing a host in the presence of diamines and the like (JP-A-5-260986 corresponding to EP-A-591605 and U.S. Patent 5,369,020).

The medium to be used in the production process of the present invention is an amino acid-containing medium, especially a medium which contains at least 1 amino acid selected from neutral amino acids such  
 45 as glycine (to be referred to as "Gly" hereinafter), Ala, Ser, Val, leucine (to be referred to as "Leu" hereinafter), Ile, Cys, Phe, Trp or Proline (to be referred to as "Pro" hereinafter), acidic amino acids such as Asp or Glu and basic amino acids such as Arg or His. An example of a medium capable of markedly increasing HSA productivity when used in the culturing of an HSA-producing host is a medium which contains at least 1 amino acid selected from the group consisting of Ala, Arg, Asp, Glu, Gly, His, Phe, Ser,  
 50 Trp, Cys, Ile and Val, preferably a medium which contains at least 1 amino acid selected from the group consisting of Ala, Asp, Glu, His, Phe, Ser, Trp and Val, more preferably a medium which contains at least 1 amino acid selected from the group consisting of Ala, Asp, His, Ser, Trp and Val. On the other hand, in comparison with an amino acid-free medium, a medium which contains at least 1 amino acid selected from the group consisting of Ala, Arg, His, Ser, Trp, Phe, and Val is effective in producing HSA in a large  
 55 quantity without allowing an HSA-producing host itself to grow when used in the culturing of the host.

Production of a large quantity of HSA by not allowing the host cells themselves to grow significantly is advantageous especially in the case of an expression system in which HSA is allowed to secrete into culture supernatant, because the ratio of culture supernatant to the amount of culture broth (medium)

becomes large so that HSA can be recovered in a higher yield.

A medium which contains His is particularly preferred as the medium to be used in the present invention. This medium is especially good for improving productivity of HSA, because it can considerably increase production yield of HSA independent of the growth of the HSA-producing host itself.

5 The medium to be used in the present invention may contain the above-described amino acid alone or as a mixture of two or more amino acids.

The amino acid content of the medium may range, for example, from about 0.08 to 20 w/v %, preferably from about 0.1 to 1 w/v %.

10 Other components of the medium to be used in the present invention are not particularly limited, provided that the medium contains at least one of the above-described amino acids. Examples of other components are those which are contained in known culture media generally used in this field. In general, various sugars are used as carbon sources, urea, ammonium salts, nitrates and the like are used as nitrogen sources and various vitamins, nucleotides and the like are used as trace nutrients, as well as inorganic salts such as of Mg, Ca, Fe, Na, K, Mn, Co, Cu and the like.

15 Illustrative examples of the useful medium include YNB liquid medium (0.7% Yeast Nitrogen Base without amino acids (manufactured by Difco) and 2% glucose), MeOH-ammonium acetate medium (composition: cf. Examples), YPD liquid medium (1% Yeast Extract (Difco), 2% Bacto-peptone (Difco) and 2% glucose) and the like. When the HSA-producing host is a methanol assimilating strain, a methanol-containing medium may be used. In that case, the methanol concentration may range approximately from 20 0.01 to 5%.

In other words, the medium to be used in the present invention can be prepared easily, by adding the above-described amino acid(s) to any known medium.

The pH of the medium may be neutral, slightly basic or slightly acidic. Preferably, the medium may have a pH value of from about 5.7 to 6.5.

25 Culture conditions may be selected in the usual way.

The culture temperature may range, for example, generally from about 15 to 43°C. It may range from about 20 to 37°C when the host is a bacterium. It may range from about 20 to 30°C when the host is a yeast. Particularly, the yeast host may be cultured at a temperature of generally from 21 to 29°C, preferably 21 to 28°C, more preferably 23 to 28°C, most preferably 25 to 27°C. The culture period is 30 approximately from 1 to 1,000 hours.

It is desirable to carry out a seed culturing prior to the main culturing making use of, for example, the above-described YNB or YPD liquid medium. Preferably, the seed culturing may be carried out for, for example, about 10 to 100 hours preferably at about 30°C in the case of yeast strains or about 37°C in the case of bacterial strains. The above-described amino acid(s) may also be used in the seed culturing.

35 After completion of the culturing, HSA is collected from the culture supernatant (filtrate) or cells by isolation and purification means commonly known. Illustrative examples of such means include a method in which HSA is purified by subjecting a culture supernatant (filtrate) to ultrafiltration, heat treatment, acid treatment and ultrafiltration, in that order, and then to respective treatments with cation exchanger, hydrophobic chromatography and anion exchanger (JP-A-5-317079 corresponding to EP-A-570916) and a 40 method in which HSA is decolorized by chelate resin treatment (JP-A-5-328991 corresponding to EP-A-570916).

The following examples are provided to further illustrate the present invention, but are not to be understood as limiting the scope of the present invention.

#### 45 EXAMPLE 1

##### (1) Preparation of strain to be used

A strain of *Pichia pastoris*, PC4130, has been obtained in accordance with the method disclosed in JP-A-2-104290, by substituting the AOX<sub>1</sub> gene region of *P. pastoris* GTS115 (*his* 4) with a *NorI*-digested 50 fragment of plasmid pPGP1 which contains a transcription unit by which HSA is expressed under the control of the AOX<sub>1</sub> promoter. Because of the absence of the AOX<sub>1</sub> gene, this strain has a reduced ability to grow on a medium which contains methanol as the carbon source (methanol assimilation negative strain; to be referred to as "Mut<sup>-</sup> strain" hereinafter).

55 The strain PC4130 was inoculated into 3 ml of YPD medium (1% yeast extract, 2% Bacto Peptone and 2% glucose). After 24 hours of culturing, the cells were inoculated into 50 ml of YPD medium so that the cell density was adjusted to initial turbidity with an OD<sub>540</sub> of 0.1. After 3 days of culturing at 30°C, the resulting cells again were inoculated into 50 ml of YPD medium at an initial cell turbidity of 0.1 at OD<sub>540</sub>.

Thereafter, subculturing was repeated every 3 days in the same manner. After each subculturing, cells were diluted with sterile water and poured onto a 2% MeOH-YNBw/oa.a. plate (0.7% Yeast Nitrogen Base without Amino Acids, 2% methanol and 1.5% agar powder) in an inoculum size of  $10^7$  cells/plate, followed by 5 days of culturing at 30 °C to judge the presence/absence of colonies. Twenty colonies were found on the 2% MeOH-YNBw/oa.a. plate after 12 days of the successive subculturing. Mut<sup>-</sup> strains hardly grow on the 2% MeOH-YNBw/oa.a. medium, while Mut<sup>+</sup> strains (methanol assimilation positive strains) grow well. That is, the presence of a colony means that the strain acquired the capacity of increased methanol assimilation and thus a Mut<sup>+</sup> strain was obtained. One of the thus obtained colonies was diluted appropriately with sterile water and spread onto a 2% MeOH-YNBw/oa.a. plate to isolate single colonies. One of the resulting single colonies was named GCP101.

An HSA expression plasmid pMM042 was constructed using an AOX<sub>2</sub> promoter (a mutant of the natural AOX<sub>2</sub> promoter (YEAST, 5, 167-177, 1988; Mol. Cell. Biol., 9, 1316-1323, 1989), in which the 255th base upstream from the initiation codon of said promoter is changed from T to C) isolated from the above-described strain GCP101. The thus constructed plasmid was introduced into *Pichia pastoris* GTS115 to obtain a transformant UHG42-3 (JP-A-4-299984 or EP-A-506040).

## (2) Medium composition

YPD medium (2% Bacto-peptone, 1% yeast extract and 2% glucose) was used for the seed culture. A MeOH-ammonium acetate medium shown in Table 1 was used in the main culture.

Table 1

Composition of MeOH-ammonium acetate medium	
Component	Concentration (mg/l)
Methanol	40 ml
Glycerol	1,000
CH <sub>3</sub> COONH <sub>4</sub>	5,000
KH <sub>2</sub> PO <sub>4</sub>	10,000
CaCl <sub>2</sub> 2H <sub>2</sub> O	100
KCl	2,000
NaCl	100
MgSO <sub>4</sub> 7H <sub>2</sub> O	2,000
ZnSO <sub>4</sub> 7H <sub>2</sub> O	100
CuSO <sub>4</sub> 5H <sub>2</sub> O	5
FeCl <sub>3</sub> 6H <sub>2</sub> O	100
Biotin	0.1
Vitamin B <sub>1</sub>	10
Vitamin B <sub>6</sub>	1
Sodium pantothenate	10
Inositol	50

## (3) Culturing method

### i) Seed culture

A 1 ml portion of the strain contained in a freeze-dried stock vial was inoculated into a 300-ml baffled Erlenmeyer flask containing 50 ml of YPD medium and cultured at 30 °C for 24 hours with shaking.

### ii) Main culture

A 1 ml portion of the seed culture medium was inoculated into a 300-ml baffled Erlenmeyer flask containing 50 ml of the MeOH-ammonium acetate medium which had been supplemented with each amino acid to give a final concentration of 0.1% and adjusted to pH 6.0, and cultured at 30 °C for 89 hours with shaking.

REFERENCE EXAMPLE 1Measurement of cell density

5 During the main culturing carried out in Example 1 (3) ii), the culture broth was sampled at optional intervals, each of the thus collected samples was diluted with distilled water to give the OD<sub>540</sub> value of 0.3 or less at the time of measurement, and then absorbance of the diluted sample at 540 nm was measured using a spectrophotometer (UV 200, manufactured by Shimadzu Corp.).

REFERENCE EXAMPLE 2Evaluation of rHSA productivity

15 The entire portion of the culture broth after completion of the culturing was recovered and subjected to 20 minutes of centrifugation at 3,000 rpm. The resulting supernatant was clarified by filtering it through MILLEX-HV (Millipore Corp.; 0.45  $\mu$ m), and a 15 ml portion of the resulting filtrate was concentrated about 20-fold using Amicon CentriPrep 10 (molecular weight cutoff of 10,000, manufactured by Amicon Corp.) (4°C, 3,000 rpm, about 6 hours) and then subjected to HPLC gel filtration analysis under the following conditions to evaluate HSA productivity:

20 Column : TSK gel G3000SW<sub>x1</sub> (Tosoh Corp.)

Mobile phase: 0.3 M NaCl, 50 mM Na-Phosphate, 0.1% NaN<sub>3</sub>, pH 6.5

Flow rate : 0.7 ml/min

Injection : 50  $\mu$ l

Detection : A<sub>280</sub>, A<sub>350</sub> (dual wave length)

25

REFERENCE EXAMPLE 3Evaluation of coloring degree of produced HSA

30

A<sub>350</sub>/A<sub>280</sub> values were calculated using the results of the HPLC gel filtration analysis carried out for the evaluation of HSA productivity, and these values were used for the evaluation of coloring degree of HSA produced by the process of the present invention.

TEST EXAMPLE 1

35

Effects of each amino acid contained in the medium were examined. Amino acid content of the medium was fixed to 0.1 w/v %. Other conditions including culture conditions were as described in Example 1. The results are shown in Tables 2 to 4. Productivity of HSA, amount of cells and degree of coloring are respectively shown by percentage based on the case of no amino acid addition as 100%.

40

Table 2

45	Amino acid and other components	Yield (%)	Cell Yield (%)	Coloring degree (%)
	Control	100	100	100
	Yeast extract	157	118	127
	Peptone	122	120	122
	Gly	127	123	145
50	Ala	220	99	112
	Asp	258	111	135
	Arg	132	98	125
	Glu	173	109	145
	His	410	76	96
55	Ile	144	105	118
	Lys	42	83	104
	Met	28	24	124

Table 3

Amino acid and other components	Yield (%)	Cell yield (%)	Coloring degree (%)
Control	100	100	100
His	439	65	72
Lys	21	44	97
Ala	146	103	109
Asp	221	107	131
Trp	238	91	215
Val	235	87	102
Leu	117	102	111
Ser	200	91	105
Thr	105	103	137
Asn	119	121	139
Gln	78	113	105
Pro	114	115	135
Ca pantothenate	72	106	120

Table 4

Amino acid	Yield (%)	Cell yield (%)	Coloring degree (%)
Control	100%	100%	100%
Phe	165	89	112
Cys	134	98	161

**TEST EXAMPLE 2**

Effects of amino acid concentrations (0.01 to 1 w/v %) in the medium were examined. His was used as the amino acid. Other conditions including culturing conditions were as described in Inventive Example 1. The results are shown in Table 5.

Table 5

Amino acid	Concentration % (w/v)	Yield (%)	Cell Yield (%)	Coloring degree (%)
Control		100	100	100
His	0.1	326	82	112
His	0.2	214	67	88
His	0.3	188	86	71
His	0.4	185	89	71
His	0.6	159	71	76
His	1.0	133	85	71

As is evident from the above test results, yield of HSA can be increased significantly when an HSA-producing host is cultured in a medium which contains an amino acid, especially Ala, Asp, Glu, His, Phe, Trp, Val or Ser. When compared with an amino acid-free culture system, it was found that the HSA yield-increasing effect of a medium which contains Ala, His, Phe, Trp, Val or Ser or a medium which contains Arg or Cys was not due to an increase in the cell yield.

According to the present invention, yield of HSA by an HSA-producing host prepared by gene manipulation techniques can be increased by employing a process which can be carried out easily with a relatively low cost by simply changing culture conditions. In particular, the HSA production yield can be increased 1.5 to 5 times in comparison with the case of culturing with no supplement of amino acids, when cultured using a medium which contains at least one amino acid selected from Ala, Asp, Glu, His, Phe, Trp,


Val and Ser. In addition, according to a process which uses a medium supplemented with at least one amino acid selected from Ala, His, Phe, Trp, Val, Ser, Arg and Cys, the HSA production yield can be increased 1.3 to 5 times independent of the cell growth. Such an effect is particularly significant in a His-containing medium. Also, the HSA productivity-increasing effect can be obtained even with a relatively small amino acid content of 0.08 to 1 w/v %. In addition, some of the above-described amino acids can reduce coloring of the produced HSA.

On the basis of these effects, the HSA production process of the present invention can be regarded as practically useful.

While the instant invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

### Claims

1. A process for producing recombinant human serum albumin which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques, in an amino acid-containing medium.
2. The process for producing recombinant human serum albumin according to claim 1 wherein said medium contains at least one amino acid selected from the group consisting of alanine, aspartic acid, arginine, cysteine, glutamic acid, histidine, isoleucine, phenylalanine, serine, tryptophan and valine.
3. The process for producing recombinant human serum albumin according to claim 1 wherein said medium contains at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, phenylalanine, tryptophan and valine.
4. The process for producing recombinant human serum albumin according to claim 1 wherein said medium contains at least one amino acid selected from the group consisting of alanine, aspartic acid, histidine, serine, tryptophan and valine.
5. The process for producing recombinant human serum albumin according to claim 1 wherein said medium contains at least one amino acid selected from the group consisting of alanine, arginine, histidine, phenylalanine, serine, tryptophan and valine.
6. The process for producing recombinant human serum albumin according to claim 1 wherein said medium contains histidine.
7. The process for producing recombinant human serum albumin according to claims 1-6, wherein said medium contains said at least one amino group in an amount of 0.08 to 20 w/v%.
8. The process for producing recombinant human serum albumin according to claim 7, wherein said medium contains said at least one amino group in an amount of 0.1 to 1.0 w/v%.
9. The process for producing recombinant human serum albumin according to claims 1-8, wherein said human serum albumin-producing host is a microorganism or an animal cell.
10. The process of claim 9 wherein said microorganism is a yeast strain.
11. The process of claim 9 wherein said microorganism is selected from the group consisting of *Escherichia coli*, a yeast strain, and *Bacillus subtilis*.
12. The process of claim 10 wherein said yeast strain is a member of the genus *Saccharomyces*, *Pichia* or *Hansenula*.
13. The process of claim 12 wherein said member of said genus *Saccharomyces* is *Saccharomyces cerevisiae* AH22.
14. The process of claim 12 wherein said member of said genus *Pichia* is *Pichia pastoris* GTS115.



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 683 233 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
03.05.2000 Bulletin 2000/18

(51) Int. Cl.<sup>7</sup>: **C12N 15/14, C12P 21/02,  
C12N 1/19, C12N 1/21**

(43) Date of publication A2:  
22.11.1995 Bulletin 1995/47

(21) Application number: **95107621.5**

(22) Date of filing: **18.05.1995**

(84) Designated Contracting States:  
**BE CH DE DK ES FR GB IT LI NL SE**

(30) Priority: **18.05.1994 JP 10399494**

(71) Applicant:  
**YOSHITOMI PHARMACEUTICAL INDUSTRIES,  
LTD.  
Chuo-ku, Osaka-shi (JP)**

(72) Inventors:  
• Ohda, Toyoo,  
The Green Cross Corp. C. Res. Lab.  
Hirakata-shi, Osaka (JP)  
• Ohtani, Wataru,  
The Green Cross Corp. C. Res. Lab.  
Hirakata-shi, Osaka (JP)  
• Ohya, Tomoshi,  
The Green Cross Corp. C. Res. Lab.  
Hirakata-shi, Osaka (JP)

- Kuwae, Shinobu,  
The Green Cross Corp. C. Res. Lab.  
Hirakata-shi, Osaka (JP)
- Tomomitsu, Kenji,  
The Green Cross Corp. C.  
Hirakata-shi, Osaka (JP)
- Kobayashi, Kaoru,  
The Green Cross Corp. C.  
Hirakata-shi, Osaka (JP)
- Ohmura, Takao,  
The Green Cross Corp. C.  
Hirakata-shi, Osaka (JP)

(74) Representative:  
**Hansen, Bernd, Dr. Dipl.-Chem. et al  
Hoffmann Eitle,  
Patent- und Rechtsanwälte,  
Arabellastrasse 4  
81925 München (DE)**

(54) **Process for producing recombinant human serum albumin**

(57) A process for producing recombinant human serum albumin is disclosed, which comprises culturing a human serum albumin-producing host, prepared by gene manipulation techniques in a medium that contains an amino acid, preferably at least one amino acid selected from the group consisting of alanine, aspartic acid, glutamic acid, histidine, serine, tryptophan, valine, isoleucine, phenylalanine, cysteine and arginine, more preferably histidine. The process can significantly increase the yield of human serum albumin over that produced by known processes.

EP 0 683 233 A3

EP 0 683 233 A3



European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**

under Rule 46, paragraph 1 of the European Patent  
Convention

Application Number

EP 95 10 7621

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (InCL6)
X	EP 0 308 381 A (SKANDIGEN AB; MTA SZEGEDI BIOLOG KOEZPONTI (HU); VEPEX CONTRACTOR) 22 March 1989 * page 97, line 60 - page 98, line 1 * * page 100, line 65 - page 101, line 1 *	1-14	C12N15/14 C12P21/02 C12N1/19 C12N1/21
X	EP 0 591 605 A (GREEN CROSS CORP) 13 April 1994 * claim 6 *	1-14	
X	LATTA M ET AL: "SYNTHESIS AND PURIFICATION OF MATURE HUMAN SERUM ALBUMIN FROM ESCHERICHIA-COLI." BIO/TECHNOLOGY, (1987) 5 (12), 1309-1314. CODEN: BTCHDA. ISSN: 0733-222X., XP002100521 * page 1313, column 2, line 4 - line 7 * --- -/--	1-9,11	
			TECHNICAL FIELDS SEARCHED (InCL6)
			C12P C07K
<b>LACK OF UNITY OF INVENTION</b>			
The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:			
see sheet B			
The present partial European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.			
Place of search		Date of completion of the search	Examiner
MUNICH		20 April 1999	Hardon, E
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (3-92) (P4/C27)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 95 10 7621

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	OKABAYSHI K ET AL: "SECRETORY EXPRESSION OF THE HUMAN SERUM ALBUMIN GENE IN THE YEAST, SACCHAROMYCES CEREVISIAE" JOURNAL OF BIOCHEMISTRY, vol. 110, no. 1, 1991, pages 103-110, XP000610608 * page 104, column 1, line 13 - column 2, line 2 *	1-14	
X	BARASH I ET AL: "SYNTHESIS AND SECRETION OF HUMAN SERUM ALBUMIN BY MAMMARY GLAND EXPLANTS OF VIRGIN AND LACTATING TRANSGENIC MICE" TRANSGENIC RESEARCH, vol. 2, 1993, pages 266-276, XP000654327 * page 267, column 2, line 13 - line -20 *	1-9	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	EP 0 606 917 A (GREEN CROSS CORP). 20 July 1994 * the whole document *	1-14	



European Patent  
Office

LACK OF UNITY OF INVENTION  
SHEET B

Application Number

EP 95 10 7621

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-5 (partially), 6, 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing histidine.

2. Claims: 1-5 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing alanine.

3. Claims: 1-4 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing aspartic acid.

4. Claims: 1, 2, 5, 7-14 (all partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing arginine.

5. Claims: 1, 7-14 (all partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing cysteine.

6. Claims: 1-3 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing glutamic acid.

7. Claims: 1-2 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing isoleucine.

8. Claims: 1, 5, 7-14 (all partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing phenylalanine.

9. Claims: 1-5 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing serine.



European Patent  
Office

LACK OF UNITY OF INVENTION  
SHEET B

Application Number  
EP 95 10 7621

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

10. Claims: 1-5 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing tryptophan.

11. Claims: 1-5 (partially), 7-14 (partially)

Process for producing recombinant HSA comprising culturing the host in a medium containing valine.

The present set of claims does not fulfil the requirements of Article 82 and Rule 30 EPC.

Article 82 EPC requires the application to relate to one invention only or to a group of inventions linked by a single general inventive concept. Rule 30 (1) EPC stipulates that where a group of inventions is claimed the requirement of unity shall be fulfilled only where there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. "Special" technical features are those features that define a contribution which each of the inventions makes over the prior art.

The common technical feature(s) in the presently claim processes is/are the presence of one or more amino acids to the culture medium of a recombinant HSA-producing host. However, the inclusion of histidine in the medium of a HSA-producing yeast has been disclosed in EP-A-0308381 (Skandigen AB). The addition of "basic amino acids", preferably arginine or lysine has been proposed for HSA-producing hosts in an earlier application of the present applicant (EP-A-0591605). This/these feature(s) thus cannot provide a common inventive concept for the claimed processes. No "corresponding feature" could be found either. Consequently each process characterised by the inclusion of a specific amino acid has to be considered a separate potential invention.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 95 10 7621

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-04-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0308381	A	22-03-1989	SE 459586 B	17-07-1989
			AT 135740 T	15-04-1996
			AU 2420488 A	17-04-1989
			DD 282473 A	12-09-1990
			DE 3855122 D	25-04-1996
			DE 3855122 T	17-10-1996
			DK 64990 A,B,	14-05-1990
			JP 2865683 B	08-03-1999
			JP 3501323 T	28-03-1991
			SE 8703539 A	15-03-1989
			WO 8902467 A	23-03-1989
			US 5879907 A	09-03-1999
EP 0591605	A	13-04-1994	JP 2080000 C	09-08-1996
			JP 5260986 A	12-10-1993
			JP 7102147 B	08-11-1995
			CA 2091636 A	17-09-1993
			US 5369020 A	29-11-1994
EP 0606917	A	20-07-1994	JP 6209763 A	02-08-1994
			US 5643792 A	01-07-1997